Nuvectis Pharma Inc. (NVCT)
Nuvectis Pharma Statistics
Share Statistics
Nuvectis Pharma has 23.39M shares outstanding. The number of shares has increased by 27.43% in one year.
| Shares Outstanding | 23.39M |
| Shares Change (YoY) | 27.43% |
| Shares Change (QoQ) | 21.07% |
| Owned by Institutions (%) | 7.67% |
| Shares Floating | 12.11M |
| Failed to Deliver (FTD) Shares | 1.84K |
| FTD / Avg. Volume | 1.54% |
Short Selling Information
The latest short interest is 1.48M, so 7.65% of the outstanding shares have been sold short.
| Short Interest | 1.48M |
| Short % of Shares Out | 7.65% |
| Short % of Float | 17.85% |
| Short Ratio (days to cover) | 12.77 |
Valuation Ratios
The PE ratio is -4.87 and the forward PE ratio is -6.65. Nuvectis Pharma's PEG ratio is 0.22.
| PE Ratio | -4.87 |
| Forward PE | -6.65 |
| PS Ratio | 0 |
| Forward PS | 1.8 |
| PB Ratio | 9.53 |
| P/FCF Ratio | -7.56 |
| PEG Ratio | 0.22 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Nuvectis Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.09, with a Debt / Equity ratio of 0.
| Current Ratio | 2.09 |
| Quick Ratio | 2.09 |
| Debt / Equity | 0 |
| Debt / EBITDA | - |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.46M |
| Employee Count | 13 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -19M |
| Effective Tax Rate | 100% |
Stock Price Statistics
The stock price has increased by 17.63% in the last 52 weeks. The beta is 0.22, so Nuvectis Pharma's price volatility has been higher than the market average.
| Beta | 0.22 |
| 52-Week Price Change | 17.63% |
| 50-Day Moving Average | 7.56 |
| 200-Day Moving Average | 6.69 |
| Relative Strength Index (RSI) | 56.56 |
| Average Volume (20 Days) | 119.29K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | 0 |
| Net Income | -19M |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.11 |
Balance Sheet
The company has 18.53M in cash and 0 in debt, giving a net cash position of 18.53M.
| Cash & Cash Equivalents | 18.53M |
| Total Debt | 0 |
| Net Cash | 18.53M |
| Retained Earnings | -73.25M |
| Total Assets | 18.61M |
| Working Capital | 9.71M |
Cash Flow
In the last 12 months, operating cash flow was -12.25M and capital expenditures 0, giving a free cash flow of -12.25M.
| Operating Cash Flow | -12.25M |
| Capital Expenditures | 0 |
| Free Cash Flow | -12.25M |
| FCF Per Share | -0.72 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NVCT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for NVCT is $15, which is 60.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 60.6% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 6.34 |
| Piotroski F-Score | 2 |